On Wednesday, Following Stocks were among the “Top 50 Gainers” of U.S. Stock Market: Primero Mining Corp (NYSE:PPP), Vitesse Semiconductor (NASDAQ:VTSS), Retrophin Inc (NASDAQ:RTRX), Novogen Limited (ADR) (NASDAQ:NVGN)
Primero Mining Corp (NYSE:PPP), with shares inclined 6.54%, closed at $3.26.
Vitesse Semiconductor (NASDAQ:VTSS), with shares jumped 37.28%, settled at $5.34.
Retrophin Inc (NASDAQ:RTRX), with shares climbed 36.56%, and closed at $20.17.
Novogen Limited (ADR) (NASDAQ:NVGN), surged 25.57%, and closed at $3.88.
Latest NEWS regarding these Stocks are depicted underneah:
Primero Mining Corp. (NYSE:PPP)
On Wednesday, Primero Mining Corp. (PPP), declared its 2014 year-end Mineral Reserves and Mineral Resources, in addition to the discovery of a new high-grade vein intersected by existing infrastructure at its San Dimas mine located in Durango, Mexico.
Primero’s 2014 year-end gold Mineral Reserves declined by 9% from 2013 to 1.9 million ounces of gold, mainly as a result of higher cut-off grades applied at Black Fox and San Dimas, combined with the influence of formerly revealed decline in ounces in the Black Fox open-pit.
Primero’s focus on delivering high quality, high margin underground ounces has resulted in a 4% raise, to 5.7 grams per tonne (“g/t”), in gold Mineral Reserve grade at its platform San Dimas mine in Mexico, in addition to a 19% raise in underground gold Mineral Reserve grade to 7.5 g/t at its Black Fox mine, located near Timmins, Ontario.
Primero has raised 2014 year-end gold and silver Measured and Indicated Mineral Resources by 1% and 4%, respectively, over 2013 year-end to comprise 3.2 million ounces of gold and 82.5 million ounces of silver.
Discovery of the Jessica vein in the Central Block, channel samples average 10.4 g/t gold and 1,606 g/t silver over 1.4 metres along 98 metres of exposed vein.
The Corporation accomplished its 2014 year-end Mineral Resource and Mineral Reserve estimation for San Dimas and Black Fox internally and retained AMC Mining Consultants (Canada) Ltd. (“AMC”) for the Grey Fox Mineral Resource estimation.
Primero Mining Corp., a precious metals producer, is engaged in the attainment, exploration, development, and production of precious metal properties in Canada and Mexico. The corporation explores for gold and silver.
Vitesse Semiconductor Corp. (NASDAQ:VTSS)
On Wednesday, Microsemi Corporation (MSCC), a leading provider of semiconductor solutions differentiated by power, security, reliability and performance, and Vitesse Semiconductor Corp. (VTSS), jointly declared that Microsemi has reached a definitive contract to attain Vitesse for $5.28 per share through a cash tender offer, representing a premium of 32 percent based on the average closing price of Vitesse’s shares of ordinary stock during the 30 trading days ended March 17, 2015. The board of directors of Vitesse unanimously recommends that Vitesse’s stockholders tender their shares in the tender offer. The total transaction value is about $389 million.
Headquartered in Camarillo, California, Vitesse designs a diverse portfolio of high-performance semiconductors, application software, and integrated turnkey systems solutions for carrier, enterprise and Internet of Things (IoT) networks worldwide. Vitesse’s products enable the fastest-growing network infrastructure markets counting mobile access/IP edge, enterprise cloud access, and industrial-IoT networking.
Microsemi anticipates noteworthy synergies from this transaction and anticipates to see immediate accretion in the first full quarter of completion. Based on current assumptions, Microsemi anticipates the attainment to be $0.16 to $0.20 per share accretive in its first full fiscal year ending September 30, 2016.
As of this date, Microsemi remains comfortable with its Jan. 22, 2015 non-GAAP guidance for its second fiscal quarter of 2015, ending March 29, 2015. Microsemi presently intends to declare its second fiscal quarter results on April 23, 2015. Further details will be forthcoming.
Vitesse Semiconductor Corporation designs, develops, and markets various semiconductor products for carrier and enterprise networking applications worldwide. The corporation provides carrier Ethernet switch engines, counting mobile access equipment, such as base stations, small cells, fiber and microwave wireless backhaul products, and Ethernet access devices for delivering business services.
Retrophin, Inc. (NASDAQ:RTRX)
On Wednesday, Retrophin, Inc. (RTRX), declared that the U.S. Food and Drug Administration (FDA) has approved Cholbam (cholic acid) capsules, the first FDA approved treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for patients with peroxisomal disorders (counting Zellweger spectrum disorders).
As a result of the approval, Retrophin will exercise its right to purchase from Asklepion Pharmaceuticals, LLC all worldwide rights, titles, and ownership of Cholbam and related assets. Under the terms of the contract declared on January 12, 2015, Retrophin will pay Asklepion a one-time cash payment of $27 million, in addition to about 661,278 shares of Retrophin ordinary stock (initially valued at $9 million at the time of the contract), which assumes Cholbam received an approval for a CTX indication. Asklepion will also be eligible to receive up to $37 million in cumulative sales milestones, as well as tiered royalties based on future net sales of Cholbam.
The FDA also granted Asklepion a Rare Pediatric Disease Priority Review Voucher (“Pediatric PRV”), a provision that encourages development of new drugs and biologics for the prevention and treatment of rare pediatric diseases. This voucher is designed to be transferable or sold and provides the bearer with an expedited FDA review for any new drug application. The Pediatric PRV will be transferred to Retrophin under the original terms of the contract with Asklepion.
The effectiveness of Cholbam has been demonstrated in clinical trials for bile acid synthesis disorders and the adjunctive treatment of peroxisomal disorders. There are about 30 patients presently receiving Cholbam through an open label extension of these trials. The estimated incidence of bile acid synthesis disorders due to single enzyme defects is 1 to 9 per million live births. Peroxisomal disorders are believed to affect about 1 in 50,000 live births.
Cholbam will have seven years market exclusivity in the United States conferred by its designation as an orphan drug. Retrophin anticipates to close the attainment and be able to start distributing therapy in as few as two to four weeks, subject to the satisfaction of customary closing conditions.
Retrophin, Inc., a biopharmaceutical corporation, focuses on the development, attainment, and commercialization of therapies for the treatment of serious, catastrophic, or rare diseases. It sells Chenodal, a synthetic oral form of chenodeoxycholic acid for radiolucent stones in well-opacifying gallbladders; and Thiola for the treatment of cystinuria.
Novogen Limited (NASDAQ:NVGN)
On Wednesday, Novogen Limited (NVGN), declared that one of its oncology pipeline drug candidates, Anisina (ATM-3507), has achieved a major milestone in its development, confirming the concept that comprehensive destruction of a cancer cell’s cytoskeleton can deliver a powerful anti-cancer effect.
Dr Kelly was interviewed by Channel 7 health reporter, Dr Andrew Rochford about Anisina’s potential.
Novogen Limited is engaged in the pharmaceutical research and development business in Australia. The corporation has primarily two drug technology platforms, which comprise super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). Its SBPs technology platform offers drug candidates, which comprise Cantrixil, an intra-peritoneal product intended for the treatment of abdominal cancers, such as ovarian and pancreatic cancer; Trilexium that is intended for the treatment of neural cancers, counting glioblastoma and neuroblastoma; and Trx-7 for the treatment of prostate cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
